GPT and metabolic dysfunction-associated steatohepatitis: Pharmacological management of NAFLD is recommended for subgroups of patients with progressive NASH, early-stage NASH with high risk of fibrosis (age >50 years, metabolic syndrome, diabetes, increased ALT), or active NASH with necroinflammatory activity [2].